Pfizer wins bid to invalidate GSK's patents over RSV vaccine
WEB6 hours ago · LONDON, Oct 7 (Reuters) - Pfizer (PFE.N), opens new tab on Monday won a bid in a London court to invalidate two of GSK's (GSK.L), opens new tab patents relating to a respiratory syncytial virus ...
ViiV Healthcare to triple annual supply of long-acting HIV PrEP ... - GSK
WEB16 hours ago · GSK plc (LSE/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has today shared the company’s commitment to make at least two million doses of long-acting cabotegravir for HIV pre-exposure prophylaxis (CAB LA for PrEP) available for procurement for low ...
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
WEB4 days ago · J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares closed yesterday at p1,497.25.
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
Goldman Sachs Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
WEB4 days ago · Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £18.00. The company’s shares closed yesterday at p1,497.25.
GSK shares tumble after Delaware court ruling on Zantac - Financial Times
WEBJun 3, 2024 · GSK shares dropped almost 10 per cent on Monday after a ruling from a Delaware judge left the UK drugmaker exposed to US jury trials over its allegedly carcinogenic heartburn treatment Zantac.
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · Core operating profit +27% (with further positive impact of +8% ex COVID) and Core EPS +28% (with further positive impact of +9% ex COVID). This reflected strong sales and SG&A leverage, partly offset by increased investment in …
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older.
GSK Lifts Guidance After HIV, Cancer Treatments Boost Sales
WEBJul 31, 2024 · GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO
WEB12 hours ago · Based on recent results from iTeos and GSK, as well as Gilead and Arcus, it appears the tide may be beginning to turn. At ESMO, iTeos and GSK reported that after at least 5.6 months of follow-up, 60% of patients given the belrestotug/Jemperli combo had an objective response, compared to about 30% of those given Jemperli alone.